 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 854058
Online Users : 1440
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/10984
|
| Title: | Dipyridamole decreases dialysis risk and improves survival in patients with pre-dialysis advanced chronic kidney disease |
| Authors: | Kuo, KL;Hung, SC;Tseng, WC;Liu, JS;Lin, MH;Hsu, CC;Tarng, DC |
| Contributors: | Institute of Population Health Sciences |
| Abstract: | Introduction: Dipyridamole decreases proteinuria and improves renal function progression in patients with glomerular disease through its inhibition of platelet activation and enhanced nitric oxide expression. Few studies have evaluated the effects of dipyridamole on renal outcome or survival in CKD stage 5 patients who have not yet received dialysis (CKD 5 ND). Materials and Methods: A prospective cohort study was conducted based on the Taiwan National Health Insurance Research Database. From January 1, 2000 to June 30, 2009, we enrolled 28,497 patients who had a serum creatinine > 6 mg/dL and a hematocrit < 28% and who were treated with erythropoiesis-stimulating agents (ESAs). All patients were further divided into two groups with or without dipyridamole use within 90 days after starting ESA therapy. Patient followed-up took place until dialysis, death before initiation of dialysis or December 31, 2009. The primary outcomes were long-term dialysis and death before initiating dialysis. Results: The dipyridamole users and nonusers groups included 7,746 and 20,751 patients, respectively. We found that 20,152 patients (70.7%) required long-term dialysis and 5,697 patients (20.0%) died before a progression to end-stage renal disease required dialysis. After propensity score-matching, dipyridamole users were associated with lower risks for long-term dialysis (adjusted HR, 0.96; 95% CI, 0.93-0.99) and death (adjusted HR, 0.91; 95% CI, 0.85-0.97) compared with nonusers. Conclusions: Dipyridamole exhibited a protective effect in reducing the risk for long-term dialysis and death among CKD 5 ND patients. Randomized studies are needed to validate this association. |
| Date: | 2018-08-03 |
| Relation: | Oncotarget. 2018 Aug 3;9(4):5368-5377. |
| Link to: | http://dx.doi.org/10.18632/oncotarget.19850 |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000422651700084 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85040458219 |
| Appears in Collections: | [許志成] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| SCP85040458219.pdf | | 1941Kb | Adobe PDF | 333 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
